Literature DB >> 16818917

Hepatitis C: reviewing the options.

Michal R Pijak.   

Abstract

Mesh：

Year:  2006        PMID： 16818917      PMCID： PMC1482764          DOI： 10.1503/cmaj.1060092

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

Authors:  Michael von Wagner; Miriam Huber; Thomas Berg; Holger Hinrichsen; Jens Rasenack; Tobias Heintges; Alexandra Bergk; Christine Bernsmeier; Dieter Häussinger; Eva Herrmann; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

2.  Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.

Authors:  T Poynard; J McHutchison; Z Goodman; M H Ling; J Albrecht
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

3.  Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

Authors:  Stephen A Harrison; Elizabeth M Brunt; Rizwan A Qazi; Dana A Oliver; Brent A Neuschwander-Tetri; Adrian M Di Bisceglie; Bruce R Bacon
Journal:  Clin Gastroenterol Hepatol       Date:  2005-06       Impact factor: 11.382

Review 4.  Hepatitis C: a review for primary care physicians.

Authors:  Tom Wong; Samuel S Lee
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

5.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

Authors:  Alessandra Mangia; Rosanna Santoro; Nicola Minerva; Giovanni L Ricci; Vito Carretta; Marcello Persico; Francesco Vinelli; Gaetano Scotto; Donato Bacca; Mauro Annese; Mario Romano; Franco Zechini; Fernando Sogari; Fulvio Spirito; Angelo Andriulli
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

6.  Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.

Authors:  Olav Dalgard; Kristian Bjøro; Kjell Block Hellum; Bjørn Myrvang; Ståle Ritland; Kjell Skaug; Nils Raknerud; Helge Bell
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

7.  Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

Authors:  Stefan Zeuzem; Rolf Hultcrantz; Marc Bourliere; Tobias Goeser; Patrick Marcellin; Jose Sanchez-Tapias; Christoph Sarrazin; Joann Harvey; Clifford Brass; Janice Albrecht
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

8.  Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

Authors:  Thierry Poynard; Vlad Ratziu; John McHutchison; Michael Manns; Zachary Goodman; Stefan Zeuzem; Zobair Younossi; Janice Albrecht
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.